Effects of Exercise During the Acute Phase of Burns

Burns Clinical Trial

Official title:

Effects of Exercise During the Acute Phase of Burns: A Multicenter Trial in Belgium

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04511104
• Other study ID #: 11B8619N[BEL]
• Status: Recruiting
• Phase: Phase 2
• Start date: May 4, 2020
• Est. completion date: April 1, 2022

Study information

• Verified date: August 2020
• Source: Universiteit Antwerpen
• Contact: David R Schieffelers
• Phone: +3232659177
• Email: david.schieffelers[@]uantwerp.be
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

BACKGROUND:

Postburn changes in whole-body, glucose and protein metabolism are at their peak during the acute phase of severe burns. The resulting metabolic derangements lead to substantial muscle wasting, insulin resistance, which ultimately hampers full recovery and reintegration into society.

PURPOSE:

This quasi-experimental trial was initiated to investigate the effects of exercise-based rehabilitation on muscle wasting, insulin resistance, and quality of life during the acute phase of severe adult burns.

METHODS:

Moderate to severely burned adults (10-80%TBSA) will be recruited from two Belgian burn centres.

Subjects allocated to the intervention group will undergo an up to 8-week-long exercise program in addition to standard care rehabilitation. As part of the exercise program, participants will carry out progressive resistance and aerobic training, initiated as soon as medical safety and patient cooperation allow. Exercise type and dosage will be chosen according to patient status in terms of grafts, mobility, and strength.

The control group will receive standard care rehabilitation only, including passive, assisted, active range of motion exercise, functional exercise, and scar treatment.

The effect on muscle wasting will be determined by B-mode ultrasound-derived measures of quadriceps muscle layer thickness (QMLT) and rectus femoris cross sectional area, as well as peak force measurements by handheld dynamometry. Insulin resistance will be derived from the HOMA-2 index based on fasting plasma glucose and insulin. Quality of life will be determined by the EQ-5D-5L and Burn Specific Health Scale-Brief (BSHS-B) questionnaires.

The results of this clinical research will provide insight into the effects of exercise on both a fundamental and clinical spectrum.

Description:

The added exercise intervention is initiated in line with the following readiness criteria, which will be checked prior to each training session:

Criteria:

• Mean arterial pressure (MAP) 60 - 110 mmHg

• Fraction of inspired oxygen (FiO2) <60%

• Partial pressure of oxygen / fraction of inspired oxygen (PaO2/FiO2) >200

• Respiratory rate <40 bpm

• Positive end expiratory pressure (PEEP) <10 cmH2O

• No high inotropic doses (Dopamine >10 mcg/kg/min or Nor/adrenaline <0,1 mcg/kg/min)

• Temp. 36 - 38,5°C

• Richmond Agitation Sedation Scale (RASS) -2 - +2

• Medical Doctor clearance

• Medical research council (MRC) score lower limbs ≥3

Accordingly, the post burn starting time differs per enrolled subject.

Exercises are administered as in-bed exercises or out-of-bed exercises, depending on whether subjects are able and allowed to engage in out-of-bed mobility.

Goal exercise intensity for resistance training is set at 60% peak force based on a weekly peak force measurement by hand-held dynamometry, or on a 3 RM in case of out of bed exercises. Goal aerobic exercise intensity is set at 50-75% peak Watts determined by a weekly cycle ergometer or treadmill ramp protocol.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: April 1, 2022
• Est. primary completion date: April 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• =10 - =80 %TBSA

• Burn depth: 2nd deep / 3rd degree

Exclusion Criteria:

• Electrical burn (except flash burns)

• Associated injury: fracture lower limb

• Diabetes Mellitus type 1

• Central neurological/neuromuscular disorders (interfering with assessment/exercise)

• Cognitive / psychological disorders (interfering with cooperation)

• Cardiopulmonary disease (interfering with exercise safety)

• Pregnancy

• Palliative care

Related Conditions & MeSH terms

• Burns

Intervention

Other:
• Exercise
Resistance and aerobic exercise in addition to standard of care rehabilitation
• Standard of Care
Standard of care rehabilitation

Locations

Country	Name	City	State
Belgium	Ziekenhuis Netwerk Antwerpen Stuivenberg	Antwerp
Belgium	Militaire Hospitaal Koningin Astrid, Neder-Over-Heembeek	Brussels

Sponsors (2)

Lead Sponsor	Collaborator
Universiteit Antwerpen	Research Foundation Flanders

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Change in isometric peak force (knee extension)	Method: Hand-held dynamometry (Lafayette instrument Co. Europe, U.K.). Isometric peak fore is measured by a 'make' manoeuvre with a fixation band disallowing movement.; Test position: Supine with a fixation band fixed to the hospital bed. Analysis: Best of 3 trials	Baseline - Hospital discharge (max. 8 weeks)
Other	Change in isometric peak force (hip flexion)	Method: Hand-held dynamometry (Lafayette instrument Co. Europe, U.K.). Isometric peak fore is measured by a 'make' manoeuvre with a fixation band disallowing movement.; Test position: Supine with a fixation band fixed to the hospital bed. Analysis: Best of 3 trials	Baseline - Hospital discharge (max. 8 weeks)
Other	Change in isometric peak force (hip extension)	Method: Hand-held dynamometry (Lafayette instrument Co. Europe, U.K.). Isometric peak fore is measured by a 'make' manoeuvre with a fixation band disallowing movement.; Test position: Supine with a fixation band fixed to the hospital bed. Analysis: Best of 3 trials	Baseline - Hospital discharge (max. 8 weeks)
Other	Change in hand grip strength	Method: Baseline LITE hydraulic dynamometer Analysis: Best of 3 trials	Baseline - Hospital discharge (max. 8 weeks)
Other	Change in Burn Specific Health Scale-Brief (BSHS-B)	Burn-specific quality of life, measured by the Burn Specific Health Scale-Brief questionnaire (Dutch and French language version).; Total score 152 (0 worst score, 152 best score), consisting of 6 subdomains: 1) Body imagine (36 points) Simple abilities (36 points) Sexuality (24 points) Affect (32 points) Work (16 points) Interpersonal relationship (8 points)	Baseline - Hospital discharge (max. 8 weeks)
Other	Change in EQ-5D-5L	Overall quality of life, measured by EQ-5D-5L (Dutch and French language version) Total score: 25 points (0 worst score, 25 best score), consisting of 5 subdomains; Mobility (5 points) Self-care (5 points) Usual activities (5 points) pain / discomfort (5 points) Anxiety / Depression (5 points) EQ overall health assessed on a Visual Analogue Scale, Total 0-100 (0 worst, 100 best score)	Baseline - Hospital discharge (max. 8 weeks)
Other	Number of adverse events	Recording of complications during exercise: Graft take, Wound infections, Medical, Cardio-respiratory safety	Baseline - Hospital discharge (max. 8 weeks)
Primary	Change in quadriceps muscle layer thickness (QMLT)	Method: B-mode ultrasound on the anterior aspect of the thigh. Technique: maximal and minimal pressure Location: measured at 1/2 and 2/3 of the distance between anterior superior iliac spine and the superior pole of the patella.; Analysis: An average of 3 trials will be recorded and analyzed using dedicated software	Baseline - Hospital discharge (max. 8 weeks)
Primary	Change in rectus femoris cross sectional area (RF-CSA)	Method: B-mode ultrasound on the anterior aspect of the thigh. Technique: minimal pressure. Location: measured at the most proximal distance where the entire muscle belly is still visible on the ultrasound image.; Analysis: An average of 3 trials will be recorded and analyzed using dedicated software.	Baseline - Hospital discharge (max. 8 weeks)
Secondary	Change in insulin resistance	Method: HOMA-2 calculated by fasting plasma glucose and insulin	Baseline - Hospital discharge (max. 8 weeks)